KLP Kapitalforvaltning AS Buys 2,800 Shares of Harmony Biosciences Holdings, Inc. $HRMY

KLP Kapitalforvaltning AS increased its holdings in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 12.2% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 25,800 shares of the company’s stock after purchasing an additional 2,800 shares during the quarter. KLP Kapitalforvaltning AS’s holdings in Harmony Biosciences were worth $815,000 as of its most recent filing with the SEC.

A number of other large investors have also bought and sold shares of HRMY. Brooklyn Investment Group increased its stake in Harmony Biosciences by 1,031.9% during the 1st quarter. Brooklyn Investment Group now owns 1,064 shares of the company’s stock worth $35,000 after purchasing an additional 970 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Harmony Biosciences in the 1st quarter valued at approximately $57,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Harmony Biosciences by 15.6% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,218 shares of the company’s stock valued at $70,000 after buying an additional 299 shares during the last quarter. CWM LLC boosted its holdings in shares of Harmony Biosciences by 34.8% in the 1st quarter. CWM LLC now owns 2,704 shares of the company’s stock valued at $90,000 after buying an additional 698 shares during the last quarter. Finally, GAMMA Investing LLC boosted its holdings in shares of Harmony Biosciences by 222.9% in the 1st quarter. GAMMA Investing LLC now owns 2,929 shares of the company’s stock valued at $97,000 after buying an additional 2,022 shares during the last quarter. 86.23% of the stock is owned by institutional investors.

Harmony Biosciences Stock Performance

Harmony Biosciences stock opened at $25.95 on Friday. Harmony Biosciences Holdings, Inc. has a 12-month low of $25.91 and a 12-month high of $41.61. The company has a quick ratio of 3.80, a current ratio of 3.84 and a debt-to-equity ratio of 0.20. The business’s 50-day moving average price is $32.45 and its two-hundred day moving average price is $32.69. The stock has a market cap of $1.49 billion, a PE ratio of 8.37, a P/E/G ratio of 0.33 and a beta of 0.79.

Harmony Biosciences (NASDAQ:HRMY) last released its earnings results on Tuesday, August 5th. The company reported $0.68 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.78 by ($0.10). Harmony Biosciences had a net margin of 23.44% and a return on equity of 26.34%. The business had revenue of $200.49 million during the quarter, compared to the consensus estimate of $204.37 million. During the same quarter in the prior year, the firm earned $1.05 EPS. The business’s revenue was up 16.0% on a year-over-year basis. Harmony Biosciences has set its FY 2025 guidance at EPS. As a group, analysts expect that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Mizuho cut their price objective on Harmony Biosciences from $50.00 to $35.00 and set an “outperform” rating for the company in a report on Thursday, September 25th. Truist Financial assumed coverage on Harmony Biosciences in a report on Monday, July 21st. They set a “buy” rating and a $48.00 price target for the company. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Harmony Biosciences in a report on Tuesday. HC Wainwright lowered their price objective on Harmony Biosciences from $70.00 to $55.00 and set a “buy” rating on the stock in a research report on Thursday, September 25th. Finally, Needham & Company LLC lowered their price objective on Harmony Biosciences from $48.00 to $41.00 and set a “buy” rating on the stock in a research report on Wednesday, September 24th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $45.56.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.